Kepos Capital’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Kepos Capital’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,200	Closed	-$432K	–	419
2018 Q3	$432K	Hold	1,200	–	–	0.02%	300
2018 Q2	$439K	Buy	+1,200	New	+$427K	0.02%	290

Other funds holding EIGR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Kepos Capital's EIGR Position: Q4 2018 in Review

Kepos Capital sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2018, closing a stake of 1,200 shares — an estimated $432K sold.

Kepos Capital first reported a position in EIGR in Q2 2018 and held it in 2 quarters. The position peaked at $439K in Q2 2018. 68 funds tracked by Wall St. Rank hold EIGR as of Q4 2018.

Kepos Capital reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Kepos Capital sold 1,200 Eiger BioPharmaceuticals, Inc. shares in Q4 2018, an estimated $432K.
Kepos Capital first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2018 and held it in 2 quarters.
Kepos Capital's Eiger BioPharmaceuticals, Inc. position peaked at $439K in Q2 2018.
68 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2018.

Based on Kepos Capital's 13F filing for Q4 2018, filed 13 Feb 2019.